$4.22
Live
0.59%
Downside
Day's Volatility :7.7%
Upside
7.15%
57.11%
Downside
52 Weeks Volatility :88.85%
Upside
74.01%
Period | Nkarta Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -34.16% | 3.6% | 0.0% |
6 Months | -42.35% | 10.2% | 0.0% |
1 Year | 132.15% | 19.6% | 0.0% |
3 Years | -75.1% | 16.8% | -23.0% |
Market Capitalization | 282.2M |
Book Value | $6.42 |
Earnings Per Share (EPS) | -1.97 |
Wall Street Target Price | 17.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -15.61% |
Return On Equity TTM | -27.99% |
Revenue TTM | 385.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -36.2M |
EBITDA | -114.0M |
Diluted Eps TTM | -1.97 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.64 |
EPS Estimate Next Year | -1.71 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | -0.46 |
What analysts predicted
Upside of 310.66%
Sell
Neutral
Buy
Nkarta Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Nkarta Inc | -12.35% | -42.35% | 132.15% | -75.1% | -91.11% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Nkarta Inc | NA | NA | NA | -1.64 | -0.28 | -0.16 | NA | 6.42 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Nkarta Inc | Buy | $282.2M | -91.11% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Nkarta Inc
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 119.9%
RA Capital Management, LLC
Boxer Capital LLC
COMMODORE CAPITAL LP
BlackRock Inc
Deerfield Management Co
Samsara BioCapital, LLC
nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.
Organization | Nkarta Inc |
Employees | 150 |
CEO | Mr. Paul J. Hastings |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$4.22
-0.94%
Invesco Bulletshares 2025 Hi
$4.22
-0.94%
Schwab International Dividend Equity Etf
$4.22
-0.94%
Blockchain Coinvestors Acquisition Corp.
$4.22
-0.94%
Allgiant Travel Company
$4.22
-0.94%
Rogers Corp
$4.22
-0.94%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$4.22
-0.94%
Iheartmedia
$4.22
-0.94%
Lightpath Technologies Inc
$4.22
-0.94%